Tilos Therapeutics is harnessing the power of the immune system to develop new therapies for the treatment of cancer, fibrosis and related disorders. Recent breakthroughs have demonstrated that patients with advanced forms of cancer can be cured by selective activation of the immune system. While these extraordinary findings have highlighted the power of immuno-oncology, current medications are only effective in a minority of patients and in a subset of cancers. There has been an explosion of interest in approaches that can extend the reach of the immune system to more patients and more forms of cancer. Tilos Therapeutics is bringing new insights and tools to this effort.
Tilos was founded in 2016 and is funded by Partners Innovation Fund and Boehringer-Ingelheim Venture Fund.